← Back to Search

Creatine monohydrate for Depression

Phase 3
Waitlist Available
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants with a diagnosis of Major Depressive Disorder with moderate to severe symptoms
Participants must meet criteria for major depressive episode for a duration of at least 2 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-6 weeks
Awards & highlights

Study Summary

This trial will study whether adding creatine to electroconvulsive therapy (ECT) for major depressive disorder (MDD) helps the treatment work better, causes fewer side effects, and leads to a faster response.

Eligible Conditions
  • Depression

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have been diagnosed with Major Depressive Disorder and your symptoms are moderate to severe.
Select...
You have been feeling very sad and down for at least 2 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
HAMD-17
Secondary outcome measures
QIDS

Side effects data

From 2015 Phase 4 trial • 14 Patients • NCT01514630
71%
Cold and flu symptoms
29%
Diarrhea
21%
Stomach Discomfort
14%
Muscle Cramps
7%
Lightheaded
7%
Numbness and Tingling in hands
7%
Headache
7%
Indigestion
7%
Polydipsia
7%
Swelling in Hands
7%
Nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Creatine Monohydrate

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Creatine monohydrateExperimental Treatment1 Intervention
Week 1: Creatine monohydrate 5g PO QID Week 2 up to Week 6: Creatine monohydrate 5g PO qday
Group II: PlaceboPlacebo Group1 Intervention
Week 1: Placebo 5g PO QID Week 2 up to Week 6: Placebo 5g PO qday
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Creatine monohydrate
2005
Completed Phase 4
~620

Find a Location

Who is running the clinical trial?

University of UtahLead Sponsor
1,095 Previous Clinical Trials
1,775,569 Total Patients Enrolled
23 Trials studying Depression
2,401 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any specific requirements to qualify for this clinical trial?

"This study is looking for 16 participants that suffer from depression. To be eligible, participants must meet the following requirements: A diagnosis of Major Depressive Disorder with moderate to severe symptoms, be over the age of 18, considered a good candidate for ECT based on clinical assessment, and not be pregnant or breast-feeding. ECT treatments can be received in either inpatient or outpatient setting at the University Neuropsychiatric Institute."

Answered by AI

Would this research be beneficial for elderly patients?

"The age restriction for this trial is 18 to 99 years old. In contrast, there are 202 trials for patients younger than 18 and 986 for patients that are senior citizens."

Answered by AI

Has Creatine monohydrate been federally recognized as safe?

"There is pre-existing clinical data that supports the safety of creatine monohydrate, which is why it was given a score of 3."

Answered by AI

Are there any open slots for this trial?

"Yes, as of today, this clinical trial is still recruiting patients. According to the latest update on the study's page on clinicaltrials.gov, the trial was posted on August 3, 2020 and was last updated on May 16, 2022."

Answered by AI

How many individuals are allowed to partake in this experiment?

"The latest information on clinicaltrials.gov affirms that this trial is still looking for participants. The study was created on 8/3/2020, with the most recent update on 5/16/2022. So far, they have only recruited 16 patients from 1 site."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder
Brent Michael Kious, MD, PhD 2020. "A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04504253.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top